The Centre represents one of the first medical technology innovation centres in Singapore to lead a global clinical research, regulatory and commercialisation strategy.
Singapore – Dornier MedTech, a Germany-based medical device company and wholly-owned subsidiary of Accuron MedTech, announced the opening of its Asia Pacific Headquarters and Global Clinical Innovation Centre in Singapore for its new urology unit, Dornier Aries.
The Centre represents one of the first medical technology innovation centres in Singapore to lead a global clinical research, regulatory and commercialisation strategy.
Dornier Aries is a non-surgical, drug-free treatment option that uses low intensity Extracorporeal Shockwave Therapy (Li-ESWT) for erectile dysfunction, a condition that affects about 30 percent of all men above 40 years old and has been shown to be extremely common among men with diabetes, a major disease burden globally (37.5% of men with Type 1 diabetes, 66.3% of those with Type 2 diabetes 2).
Dornier Aries is currently available in Singapore and multiple markets worldwide. The new Centre will assume full responsibility for recently initiated clinical trials on Dornier Aries in the US to support a regulatory filing with the US Food & Drug Administration. In addition, the Centre will lead new global studies to explore the potential of Dornier Aries to treat other urological indications such as chronic pelvic pain syndrome and urinary incontinence.
Dornier MedTech will invest US$30 million over the next five years to build its capabilities in Singapore, hiring more than 30 staff to execute its growth plan for Dornier Aries. Abel Ang, CEO of Dornier MedTech, and Group CEO of Accuron MedTech Group, commented: “Dornier MedTech is known as a leader in extracorporeal shockwave therapy. The opening of our new HQ and Clinical Innovation Centre is an important milestone as we continue to invest in broadening our product portfolio and, ultimately, creating new therapies for patients. Singapore’s rich, pro-innovation ecosystem and access to strong clinical and commercial capabilities will provide an important launchpad for Dornier MedTech in Asia Pacific and beyond.
“By 2025, it is expected that erectile dysfunction will affect more than 300 million men worldwide, of which 200 million men will be in Asia. The new Global Clinical Innovation Centre brings the clinical development strategy of Dornier Aries closer to the patients that need the treatment most.”
The Centre represents one of the first medical technology innovation centres in Singapore to lead a global clinical research, regulatory and commercialisation strategy.
Dornier Aries is a non-surgical, drug-free treatment option that uses low intensity Extracorporeal Shockwave Therapy (Li-ESWT) for erectile dysfunction, a condition that affects about 30 percent of all men above 40 years old and has been shown to be extremely common among men with diabetes, a major disease burden globally (37.5% of men with Type 1 diabetes, 66.3% of those with Type 2 diabetes 2).
Dornier Aries is currently available in Singapore and multiple markets worldwide. The new Centre will assume full responsibility for recently initiated clinical trials on Dornier Aries in the US to support a regulatory filing with the US Food & Drug Administration. In addition, the Centre will lead new global studies to explore the potential of Dornier Aries to treat other urological indications such as chronic pelvic pain syndrome and urinary incontinence.
Dornier MedTech will invest US$30 million over the next five years to build its capabilities in Singapore, hiring more than 30 staff to execute its growth plan for Dornier Aries. Abel Ang, CEO of Dornier MedTech, and Group CEO of Accuron MedTech Group, commented: “Dornier MedTech is known as a leader in extracorporeal shockwave therapy. The opening of our new HQ and Clinical Innovation Centre is an important milestone as we continue to invest in broadening our product portfolio and, ultimately, creating new therapies for patients. Singapore’s rich, pro-innovation ecosystem and access to strong clinical and commercial capabilities will provide an important launchpad for Dornier MedTech in Asia Pacific and beyond.
“By 2025, it is expected that erectile dysfunction will affect more than 300 million men worldwide, of which 200 million men will be in Asia. The new Global Clinical Innovation Centre brings the clinical development strategy of Dornier Aries closer to the patients that need the treatment most.”
